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Morphine hyposensitivity in streptozotocin- diabetic rats: 
Reversal by dietary l- arginine treatment



























































In	 other	work	 by	 our	 group	 in	 diabetic	 rats	 assessed	 in	 longi-
tudinal	 studies	 over	 prolonged	 periods,	 morphine	 hyposensitivity	
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developed	 in	 a	 temporal	 manner	 and	was	 fully	 developed	 by	 ap-
proximately	 3	months	 of	 diabetes	with	 it	 being	maintained	 for	 at	
least	6	months.4-6	 Interestingly,	this	time	course	mimicked	that	for	
progressive	development	of	hyposensitivity	to	the	pain-	relieving	ef-
fects	 of	 the	 furoxan	NO	 donor,	 PRG150,	 in	 STZ-	diabetic	 rats3 as 













signaling	 cascade	 and	 glial	 cell	 activation,	 to	markedly	 increase	NO	
formation	at	multiple	levels	of	the	somatosensory	nervous	system.8-10 
In	 diabetes,	 there	 is	 increased	 generation	 of	 superoxide	 that	 reacts	
with	elevated	 levels	of	NO	to	 increase	 formation	of	 the	neurotoxin,	
peroxynitrite,	 resulting	 in	nitrooxidative	stress	and	 the	development	
of	PDN.11,12
From	 the	 foregoing,	 we	 developed	 the	 hypothesis	 that	 pro-
gressive	depletion	of	endogenous	NO	bioactivity	may	have	a	key	
role	 in	 the	 temporal	 development	 of	 morphine	 hyposensitivity	
in	 STZ-	diabetic	 rats	 and	 that	 replenishment	 of	 endogenous	NO	
bioactivity	 may	 restore	 morphine	 sensitivity	 in	 these	 animals.	
To	 test	 our	 hypothesis,	 STZ-	diabetic	 rats	were	 administered	 di-
etary l-	arginine	 (NO	precursor)	 at	 1	g/d	 (2.5%	 in	 ground	 rodent	
chow)	according	to	either	a	15-	week	prevention	protocol	(Group	
1)	 commencing	 at	 3	weeks	 prior	 to	 the	 abolition	 morphine	




2.1 | Mechanical hypersensitivity in the hindpaws of 
STZ- diabetic rats
The	 mean	 (±	SEM)	 paw	 withdrawal	 thresholds	 (PWTs)	 in	 the	 bi-
lateral	 hindpaws	 of	 drug-	naïve	 STZ-	diabetic	 Dark	 Agouti	 (DA)	
rats	were	 significantly	 lower	 (P	≤	.05)	 than	 those	 for	 control	 non-	





(Figure	1),	 the	mean	 (±	SEM)	 hindpaw	 PWTs	 at	 14	 and	 24	weeks	




24	weeks	post-	STZ	administration.	 In	Group	3	 rats	 (Figure	1),	 the	
mean	(±	SEM)	hindpaw	PWT	at	24	weeks	post-	STZ	administration	
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2.2 | Dietary l- arginine prevents loss of morphine 
efficacy in STZ- diabetic rats
2.2.1 | Group 1: l- arginine prevention protocol
The	dose-	response	curve	for	single	subcutaneous	(s.c.)	bolus	doses	
of	morphine	 in	STZ-	diabetic	DA	 rats	 at	9	weeks	post-	STZ	admin-
istration	 is	 shown	 in	 Figure	2.	 The	 corresponding	 mean	 (±	SEM)	
dose	 that	produced	 a	50%	 response	 (ED50)	was	6.1	 (±	0.3)	mg/kg	
in	agreement	with	 that	 for	STZ-	diabetic	DA	rats	at	3	weeks	post-	
STZ	reported	previously	by	our	laboratory.4	Additionally,	the	mean	




DA	rats	just	prior	to	initiation	of	the	dietary	l- arginine intervention 
at	 9	weeks	 post-	STZ	 (Figure	2).	 Thus,	 administration	 of	 dietary	 l- 
arginine	for	as	little	as	3	weeks	prevented	the	abolition	of	morphine	
efficacy	 (Figure	2)	 that	otherwise	occurs	at	12	weeks	post-	STZ	as	
previously reported by our laboratory.4,5	After	15	weeks	of	dietary	
l-	arginine	treatment	in	the	same	animals	(24	weeks	post-	STZ),	acute	








2.3 | Dietary l- arginine restores morphine 
efficacy and potency in STZ- diabetic rats














efficacy	was	not	only	 retained	 in	 these	animals	 (Figure	3)	but	 there	
was	a	significant	increase	in	the	potency	of	single	s.c.	bolus	doses	of	
morphine	at	6.1	mg/kg	(F(2,11) = 14.5; P	≤	.05;	one-	way	ANOVA	with	
Tukey’s	multiple	 comparison	 test)	 (Figure	3).	Additionally,	 the	mean	
(±	SEM)	%MPE	 AUC	was	 149.5	 (±	9.5)	 %MPE.h	which	 did	 not	 dif-
fer	 (F(3,16)	=	11.5,	 P >	.05;	 one-	way	 ANOVA	 with	 Tukey’s	 multiple	
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comparison	test)	from	that	for	s.c.	morphine	at	6.1	mg/kg	in	opioid-	
naïve	non-	diabetic	control	rats	(136.9	±	16.1%MPE.h).
2.3.2 | Group 3: l- arginine late intervention protocol
In	STZ-	diabetic	DA	rats	where	morphine	efficacy	had	been	abolished	
since	12	weeks	post-	STZ	administration,4	an	8-	week	dietary	l- arginine 
intervention	 at	 1	g/d	 commencing	 at	 30	weeks	 post-	STZ	 (Figure	1),	
resulted	 in	 restoration	 of	 morphine	 efficacy	 (Figure	4).	 Specifically,	
after	 4	weeks	 of	 dietary	 l-	arginine,	 the	 mean	 (±	SEM)	 %MPE	 AUC	
value	 evoked	 by	 an	 s.c.	 bolus	 dose	 of	 morphine	 at	 6.1	mg/kg	 was	
62.2	 (±	15.8)	 %MPE.h	 (Figure	4)	 which	 did	 not	 differ	 significantly	
(F(4,23)	=	31.1,	 P >	.05;	 one-	way	 ANOVA	with	 Tukey’s	 multiple	 com-











2.3.3 | Dietary l- arginine: No effect on morphine 




give	 comparable	 doses	 of	 l-	arginine	 to	 both	 STZ-	diabetic	 and	non-	
diabetic	weight-	matched	control	rats,	the	concentration	of	l- arginine 
in	 the	 ground	 rodent	 chow	was	 2-	fold	 higher	 for	 non-	diabetic	 rats	
at	5%	c.f.	2.5%	 for	STZ-	diabetic	animals.	For	non-	diabetic	male	DA	
rats,	 the	mean	 (±	SEM)	ED50	 at	 3.0	 (±	0.2	mg/kg)	 for	 the	 antinocic-
eption	 (%MPE)	dose-	response	curve	 (Figure	5)	evoked	by	single	s.c.	
bolus	doses	of	morphine	did	not	differ	significantly	(P > .05; unpaired t 
test)	from	that	(2.5	±	0.2	mg/kg)	for	non-	diabetic	male	DA	rats	admin-
istered l-	arginine	 (1	g/d)	 for	1	week	prior	 to	antinociceptive	 testing	





crease	 in	mean	 (±	SEM)	 body	weight	 (see	 details	 in	 Supplementary	
Results	online)	and	there	was	a	marked	increase	in	blood	glucose	con-
centrations	(from	6	to	>20	mmol/L)	(Supplementary	Results).	Dietary	
administration	of	 l-	arginine	 at	1	g/d	mixed	 in	 rodent	 chow	 to	STZ-	
diabetic	rats	for	up	to	15	weeks	did	not	adversely	alter	body	weight	





15-	week	 prevention	 protocol	 (Figure	1)	 or	 an	 8-	week	 intervention	
protocol	 (Figure	1)	 in	 STZ-	diabetic	 rats	 modulated	 the	 extent	 and	



















significantly	(P > .05; unpaired t	test).	( )	No	l-	Arg;	( )	1	week	
l- Arg










Intriguingly,	 initiation	 of	 a	 dietary	 l-	arginine	 (1	g/d)	 intervention	
after	morphine	efficacy	had	been	abolished	 in	STZ-	diabetic	 rats	 (ie,	
at	 14	weeks	 post-	STZ	 for	Group	 2;	 Figure	1),	 progressively	 rescued	





In	 weight-	matched	 control,	 non-	diabetic	 rats,	 dietary	 l- arginine 
at	1	g/d	had	no	significant	 (P > .05)	effect	on	morphine	potency	rel-
ative	 to	 that	 for	 control	 non-	diabetic	 rats	 fed	 a	 standard	 rat	 chow	
diet	 (Figure	5).	Our	 findings	 are	 aligned	with	 previous	work	by	oth-





















In	 recent	 work	 by	 others	 in	 STZ-	diabetic	 rats	 exhibiting	 opioid	
hyposensitivity,	MOP	receptor	immunoreactive	primary	sensory	neu-
rons	were	 co-	localized	with	 activated	PKC	 isoforms	 as	well	 as	with	
the	 receptor	 for	 advanced	 glycation	 end	 products	 (RAGE).16	 Using	
a	 range	of	measures	 including	 administration	of	 a	 selective	PKC	 in-
hibitor,	 intrathecal	RAGE	siRNA,	or	 inhibition	of	 advanced	glycation	
end	product	(AGE)	formation	to	prevent	both	RAGE-	dependent	PKC	
activation	and	desensitization	of	the	MOP	receptor,	opioid	analgesic	
efficacy	was	 restored.16	 In	 other	work	 in	 rats	with	 advanced	diabe-
tes	at	12	weeks	post-	STZ,	the	inhibitory	effects	of	intraplantar	bolus	
doses	of	morphine	on	capsaicin-	induced	nocifensive	behaviour	were	




all	 changes	 reversed	 by	 intrathecal	 infusion	 of	 nerve	 growth	 factor	

















Although	 dietary	 supplementation	with	 l- arginine restored mor-
phine	 efficacy	 and	 potency	 in	 STZ-	diabetic	 rats	 herein,	 this	 treat-
ment	had	only	a	minor	effect	on	baseline	PWTs.	These	 findings	are	
in	contrast	to	work	by	others	where	administration	of	l- arginine as a 
prevention	protocol	in	the	drinking	water	(2.6	g/L	for	3	weeks;	water	
consumption	276	mL/d)	prevented	the	development	of	both	mechan-
ical	 and	 thermal	 hypersensitivities	 in	 the	 hindpaws	 of	 STZ-	diabetic	





assessed	the	effect	of	chronic	dietary	l- arginine on blood glucose levels 
in	rats	with	advanced	STZ-	induced	diabetes.	Importantly,	we	show	that	
irrespective	 of	when	 the	 dietary	 l- arginine intervention was initiated 
in	the	interval	9-	30	weeks	post-	STZ	administration,	it	did	not	alter	the	
markedly	elevated	blood	glucose	levels	(>20	mmol/L)	in	these	animals	
(Supplementary	 Results).	 Our	 findings	 are	 aligned	 with	 other	 work	
whereby	 intravenous	 injection	of	a	bolus	dose	of	l-	arginine	 (150	mg/
kg)	followed	by	chronic	infusion	(10	mg/kg	per	minute	for	60	minutes),	
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our	 findings	 suggest	 that	 NO	 donors	 may	 restore	 opioid	 analgesic	
efficacy	in	patients	with	advanced	diabetes.	If	so,	 it	may	be	possible	
to	 provide	 improved	 pain	 relief	 in	 diabetic	 patients	 whose	 PDN	 is	
poorly relieved by clinically available drug treatments recommended 
by	 the	Neuropathic	Pain	Special	 Interest	Group	of	 the	 International	
Association	for	the	Study	of	Pain,	such	as	the	gabapentinoids	and	the	
tricyclic antidepressants.33
In	 summary,	 our	 findings	 are	 the	 first	 to	 provide	 in	 vivo	 ev-
idence	 linking	 depletion	 of	 NO	 bioactivity	with	 the	 development	
of	morphine	hyposensitivity	in	the	STZ-	diabetic	rat	model	of	PDN.	
Specifically,	 treatment	of	STZ-	diabetic	 rats	with	dietary	 l- arginine 
at	1	g/d	for	15	weeks	according	to	a	prevention	protocol	prevented	
the	abolition	of	morphine	efficacy	that	otherwise	occurred	in	STZ-	
diabetic	 rats	 at	 12	weeks	 post-	STZ	 administration.	 Additionally,	
treatment	 of	 STZ-	diabetic	 rats	 that	were	 insensitive	 to	 the	 pain-	
relieving	effects	of	single	s.c.	bolus	doses	of	morphine,	with	dietary	
l-	arginine	at	1	g/d	for	8	weeks	according	to	an	intervention	proto-
col	progressively	 rescued	morphine	efficacy	and	potency	 in	 these	
animals	without	significantly	altering	the	underlying	peripheral	neu-
ropathic	pain	state.
4  | MATERIALS AND METHODS
4.1 | In vivo experimentation
4.1.1 | Animals
Ethics	 approval	 was	 from	 the	 Animal	 Ethics	 Committee	 of	 The	




had	 free	 access	 to	 rodent	 chow	 and	water,	 and	were	 acclimatized	
prior	to	initiation	of	experimentation.
4.2 | Reagents and materials
l-	arginine	 hydrochloride,	 streptozotocin,	 citric	 acid	 and	 trisodium	
citrate	were	from	Sigma	Aldrich	 (Sydney,	Australia).	Morphine	hy-
drochloride	 was	 from	 the	 Pharmacy	 Department,	 Royal	 Brisbane	
and	Women’s	Hospital	(Brisbane,	Australia).	Sodium	benzylpenicillin	
(Benpen)	vials	containing	600	mg	of	powder,	ketamine	hydrochlo-




(0.5	mm	 internal	 diameter)	was	 from	Critchley	Electrical	 Products	
Pty.	Ltd.	(Auburn,	Australia).	Blood	glucose	testing	strips	(Glucostix)	
were	 from	 The	 University	 of	 Queensland	 Campus	 Pharmacy	
(Brisbane,	 Australia)	 and	 a	 glucometer	 Precision	 Q.I.D	 was	 from	
Medisense	 Australia	 Pty	 Ltd	 (Melbourne,	 Australia).	 Medical	
grade CO2 and O2	were	purchased	from	BOC	Gases	Australia	Ltd.	
(Brisbane,	Australia).
4.3 | Induction of diabetes with Streptozotocin (STZ)
Anaesthesia	was	induced	with	a	mixture	of	ketamine	(100	mg/kg,	ip)	
and	 xylazine	 (16	mg/kg,	 ip)	 to	 facilitate	 insertion	 of	 a	 polyethylene	
cannula	(pre-	filled	with	0.1	mL	of	sterile	saline)	into	the	right	common	
jugular	 vein.	 Cannulae	 were	 tested	 for	 correct	 placement	 by	 with-
drawing	 a	 small	 amount	 of	 blood.	Diabetes	was	 induced	 in	 rats	 by	
injection	of	STZ	(85	mg/kg	in	0.1	mol/L	citrate	buffer	at	pH	4.5)	via	
the	jugular	vein	cannula.3-5	Benzylpenicillin	(60	mg	s.c.)	was	adminis-
tered and rats were monitored during surgical recovery. Diabetes was 
confirmed	on	day	7	post-	STZ	 in	 individual	 rats	 if	daily	water	 intake	
was	≥100	mL	and	blood	glucose	levels	(BGLs)	were	≥15	mmol/L.	Non-	
diabetic	rats	were	used	in	the	control	experiments.
4.4 | l- arginine dietary administration
A	 group	 of	 control	 non-	diabetic	 rats	 received	 dietary	 l- arginine at 
1	g/d	(5%	mixed	with	ground	rodent	chow)	for	7	days.	This	l- arginine 
dose	 was	 used	 previously	 by	 others	 in	 hypertensive	 non-	diabetic	
rats.34	A	2-	fold	 lower	 concentration	of	 l-	arginine	 (2.5%	mixed	with	
ground	 rodent	 chow)	 was	 used	 in	 STZ-	diabetic	 rats	 because	 their	
mean	(±	SEM)	food	consumption	was	2-	fold	higher	at	43.2	(±	0.2)	g/d	
compared	with	20.5	(±	0.7)	g/d	for	the	non-	diabetic	group.
4.5 | Dosing solutions and dose administration
A	stock	 solution	of	morphine	 (45	mg/mL	as	 the	 free	base	 in	 sterile	











4.6.1 | Group 1 STZ- diabetic rats: l- arginine 
prevention protocol
Group	1	DA	 rats	 (n	=	25;	 256	±	3.6	g,	mean	±	SEM)	 received	 an	 in-
travenous	 dose	 of	 STZ	 (85	mg/kg)	 and	 were	 studied	 longitudinally	
over	 a	 6-	month	 period.	 For	 each	 testing	 session,	 rats	 received	 sin-




Von	 Frey	 filaments.	 At	 9	weeks	 post-	STZ	 in	 Group	 1	 STZ-	diabetic	
rats,	dietary	l-	arginine	at	1	g/d	mixed	with	ground	rodent	chow	was	
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initiated	and	continued	until	study	completion	at	24	weeks	post-	STZ	
administration.




ied	 longitudinally	 over	 a	 6-	month	 period.	 Individual	 rats	 (n	=	6)	
received	 the	 ED50	 dose	 of	 s.c.	 morphine	 (6.1	mg/kg)	 determined	
in	 Group	 1	 rats	 at	 9	weeks	 post-	STZ	 to	 evaluate	 the	 acute	 anti-	
allodynic	 responses	 at	14,	18	and	22	weeks	post-	STZ	administra-
tion	 (Figure	2).	 PWTs	were	measured	 in	 the	bilateral	 hindpaws	at	
regular	 intervals	over	a	3-	hour	post-	dosing	period	as	for	Group	1.	
At	 14	weeks	 post-	STZ	 administration,	 an	 l- arginine dietary inter-
vention	at	1	g/d	mixed	with	ground	rodent	chow	was	initiated	and	
continued	for	8	weeks	(Figure	2).
4.6.3 | Group 3 STZ- diabetic rats: l- arginine late 
intervention protocol










4.6.4 | Control non- diabetic rats
A	group	of	opioid-	naïve,	non-	diabetic	DA	rats	(n	=	18;	215.0	±	2.0	g,	
mean	±	SEM)	 received	 one	 of	 three	 bolus	 doses	 (Figure	4)	 of	 s.c.	










4.7 | Assessment of paw withdrawal thresholds 
in the bilateral hindpaws
Mechanical	allodynia	 in	 the	bilateral	hindpaws,	a	defining	symptom	































rats.	Unpaired	 t tests were used to compare various parameters in 
non- diabetic rats administered dietary l-	arginine	at	1	g/d	for	1	week	
compared	with	similar	animals	fed	standard	rodent	chow.	The	statisti-
cal	significance	criterion	was	P < .05.	For	statistical	comparisons	using	
one-	way	ANOVA,	F values are reported as F(df	of	treatment,	residual).
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